1. Anxiety Disorders
Anxiety is the second-most-common reason patients seek medical cannabis, but the relationship is more complicated than chronic pain. THC can reduce anxiety at low doses but worsen it at higher ones, while CBD appears to have anxiety-reducing effects across a wider dose range without the psychoactive component. Generalized anxiety disorder, social anxiety, and panic disorder are most often reported. Patients typically describe a calmer baseline mood, fewer racing thoughts, and easier sleep onset rather than dramatic symptom relief. Clinical trials show moderate effects on anxiety symptoms are common but not universal. Strain selection and dose matter more here than for almost any other condition. CBD-dominant or balanced strains are preferred over high-THC options, and a clinically supervised approach typically produces better results. Some patients use cannabis as a daily baseline anxiety reducer, while others reserve it for acute episodes like social events, flights, or panic attacks.
2. Chronic Pain
Chronic pain is the single most common reason people pursue medical cannabis. Roughly 20 percent of adults globally suffer from long-term pain, and conventional options like opioids, NSAIDs, and corticosteroids carry significant downsides when used over months or years. A landmark review by the National Academies of Sciences, Engineering, and Medicine found substantial evidence that cannabis or cannabinoids are effective for treating chronic pain in adults. This places chronic pain in the strongest evidence category. Common conditions treated include neuropathic pain, fibromyalgia, lower back pain, and inflammatory pain from rheumatoid arthritis, osteoarthritis, and lupus. Cannabis offers a different side-effect profile and much lower addiction risk compared to opioids. CBD modulates the endocannabinoid system, which regulates both pain perception and inflammation, making it particularly interesting for inflammatory pain.
3. PTSD
Post-traumatic stress disorder is one of the conditions where the gap between patient-reported benefits and randomized clinical trial data is widest. Veterans, sexual assault survivors, and others with trauma-related symptoms have long reported that cannabis reduces nightmares, hypervigilance, and intrusive memories. Clinical trials are less settled but consistent enough that several Canadian provinces and US states list PTSD as a qualifying condition. Cannabis appears to help the brain process and release traumatic memories rather than reactivate them, through the endocannabinoid system's role in fear extinction. THC is particularly relevant for nightmare suppression, while CBD has been studied for its effect on conditioned fear responses. Veterans Affairs Canada covers medical cannabis for veterans with confirmed PTSD, making this one of the most studied populations. Reported reductions in nightmare frequency, alcohol use, and antidepressant dosing have been consistent enough to prompt more rigorous trials.
4. Sleep Disorders
Insomnia and other sleep disorders sit between chronic pain and anxiety as common driving complaints, often overlapping with both. Patients who can't sleep usually have an underlying reason, such as pain, racing thoughts, restless legs, or trauma-related arousal, and cannabis tends to address those underlying causes more than the sleep itself. Different cannabinoids have distinct effects: THC reduces sleep latency and shortens REM sleep, leading to fewer dreams when used before bed; CBD supports sleep mainly by lowering anxiety and cortisol levels rather than acting as a direct sedative; CBN is often marketed as a sedative, though human evidence remains thin. For shift workers, chronic pain patients, and those with treatment-resistant insomnia, medical cannabis is increasingly used as an alternative to traditional sleep medications, which carry their own dependence risks.
5. Multiple Sclerosis
Multiple sclerosis was one of the first conditions where cannabis-based medicine entered mainstream clinical use. Sativex, an oromucosal spray containing THC and CBD in a roughly equal ratio, has been approved in Canada and parts of Europe specifically for MS-related spasticity, making it one of the few cannabis products approved as a prescription pharmaceutical. The condition causes muscle stiffness, painful spasms, and bladder dysfunction in many patients. Conventional muscle relaxants often produce sedation severe enough to interfere with daily life. Cannabinoids tend to reduce spasticity with milder cognitive side effects in this population, which is why several MS societies now treat them as a legitimate adjunct to standard therapy. Patients also report relief from neuropathic pain, sleep disturbance, and bladder urgency, though evidence for spasticity relief is stronger than for these secondary symptoms.
6. Epilepsy
Epilepsy is the only condition for which a cannabis-derived drug has received full FDA approval in the United States. Epidiolex, a purified cannabidiol oral solution, was approved in 2018 for treatment-resistant seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex in patients one year and older. This was a significant moment for medical cannabis as a category, as no plant-derived cannabinoid had passed the full FDA approval process until then. The trials showed clinically meaningful seizure reductions in children whose conditions had not responded to standard antiepileptic drugs, with some experiencing more than a 50 percent drop in seizure frequency. Outside FDA-approved indications, doctors and parents have used CBD off-label for other forms of refractory epilepsy.